als-008176
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 2, 2015 (NCT02592967)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- als-008176
- jnj-64041575
- jnj-64041757
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03371381 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2018 | Janssen Pharmaceutica NV |
| NCT03189498 | Phase 1 | Jul 5, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT03105986 | Phase 1 | Apr 10, 2017 | Johnson and Johnson |
| NCT03010059 | Phase 1 | Feb 6, 2017 | Johnson and Johnson |
| NCT02592967 | Phase 1 | Dec 2, 2015 | Johnson and Johnson |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 4 | 4 | 1 | 2015 |
| Janssen Pharmaceutica NV | For profit | 2 | 1 | 2 | 2017 |
2 organizations
Page 1 / 1